Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA1931 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | MIP-1B | 65.0 | 68 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 1 | MIP-1B | 59.5 | 56 | |
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | MIP-1B | 76.0 | 49 | |
RA1869 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MIP-1B | 141.5 | 58 | |
RA1869 | IL-1 alpha | 100 | ng/mL | 1 | MIP-1B | 201.0 | 49 | ||||
N2759 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MIP-1B | 568.0 | 49 | |
N2759 | IL-1 alpha | 100 | ng/mL | 1 | MIP-1B | 374.0 | 40 | ||||
RA1931 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MIP-1B | 109.5 | 60 | |
RA1931 | IL-1 alpha | 100 | ng/mL | 1 | MIP-1B | 213.0 | 65 | ||||
N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MIP-1B | 258.0 | 63 | |
N2586 | IL-1 alpha | 100 | ng/mL | 1 | MIP-1B | 228.0 | 53 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | MIP-1B | 58.0 | 73 | |
RA1869 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | MIP-1B | 57.0 | 65 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | MIP-1B | 60.0 | 81 | |
N2759 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | MIP-1B | 66.0 | 75 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | MIP-1B | 63.0 | 65 | |
RA1931 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | MIP-1B | 60.0 | 65 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | MIP-1B | 59.0 | 74 | |
N2586 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | MIP-1B | 64.0 | 65 | |
RA1869 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 1 | MIP-1B | 60.0 | 57 | |
RA1869 | Poly(I:C) | 2 | ug/mL | 1 | MIP-1B | 98.0 | 67 | ||||
N2759 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 1 | MIP-1B | 1031.5 | 56 | |
N2759 | Poly(I:C) | 2 | ug/mL | 1 | MIP-1B | 966.0 | 55 | ||||
RA1931 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 1 | MIP-1B | 465.0 | 59 | |
RA1931 | Poly(I:C) | 2 | ug/mL | 1 | MIP-1B | 73.0 | 54 |